dc.creator | Olea, Fernanda Daniela | |
dc.creator | De Lorenzi, Andrea | |
dc.creator | Cortés, Claudia | |
dc.creator | Cuniberti, Luis Alberto | |
dc.creator | Fazzi, Lucía | |
dc.creator | Flamenco, María del Pilar | |
dc.creator | Locatelli, Paola | |
dc.creator | Cabeza Meckert, Patricia | |
dc.creator | Bercovich, Andrés | |
dc.creator | Laguens, Rubén | |
dc.creator | Crottogini, Alberto José | |
dc.date.accessioned | 2017-09-13T19:14:46Z | |
dc.date.accessioned | 2018-11-06T11:27:43Z | |
dc.date.available | 2017-09-13T19:14:46Z | |
dc.date.available | 2018-11-06T11:27:43Z | |
dc.date.created | 2017-09-13T19:14:46Z | |
dc.date.issued | 2013-05 | |
dc.identifier | Olea, Fernanda Daniela; De Lorenzi, Andrea; Cortés, Claudia; Cuniberti, Luis Alberto; Fazzi, Lucía; et al.; Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction; Elsevier Ireland; International Journal of Cardiology; 165; 2; 5-2013; 291-298 | |
dc.identifier | 0167-5273 | |
dc.identifier | http://hdl.handle.net/11336/24169 | |
dc.identifier | CONICET Digital | |
dc.identifier | CONICET | |
dc.identifier.uri | http://repositorioslatinoamericanos.uchile.cl/handle/2250/1852392 | |
dc.description.abstract | BACKGROUND: In reperfused acute myocardial infarction (RAMI), cardioprotective treatments may enhance myocardial salvage and hence reduce the area of necrosis. Based on studies showing that plasmid-mediated vascular endothelial growth factor (pVEGF) gene transfer reduces infarct size by combining angio-arteriogenic and cardiomyogenic effects and that erythropoietin (EPO) exerts anti-apoptotic actions in animal models of AMI, we aimed to assess if their association would reduce infarct size to a larger extent than any of them individually in a large mammalian model of RAMI. METHODS: Adult sheep subjected to 90-minute coronary artery occlusion received upon reperfusion intramyocardial pVEGF 3.8 mg plus intravenous EPO 1000 IU/kg (n=8), pVEGF (n=8), EPO (n=8) or placebo (n=8). RESULTS: Fifteen days after treatment, infarct size was smaller in the 3 treatment groups (pVEGF+EPO: 8 ± 1 %; pVEGF: 16 ± 5 %; EPO: 13 ± 4 %) compared to placebo (25 ± 7 %, p<0.001). However, in the EPO+VEGF group infarct size was significantly smaller than in the groups receiving EPO or VEGF individually (p<0.05). DNA fragmentation, a hallmark of late apoptosis, was significantly lower in sheep receiving EPO. The combined treatment, while not affecting global left ventricular performance, improved regional peri-infarct function and prevented over-time expansion of the post-infarct perfusion defect. CONCLUSIONS: Combined pVEGF and EPO treatment might be clinically useful to enhance the benefits of early revascularization in patients with acute myocardial infarction. | |
dc.language | eng | |
dc.publisher | Elsevier Ireland | |
dc.relation | info:eu-repo/semantics/altIdentifier/url/http://www.sciencedirect.com/science/article/pii/S0167527311009193 | |
dc.relation | info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1016/j.ijcard.2011.08.078 | |
dc.rights | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | |
dc.rights | info:eu-repo/semantics/restrictedAccess | |
dc.subject | VEGF | |
dc.subject | Erythropoietin | |
dc.subject | Reperfused myocardial infarction | |
dc.subject | Apoptosis | |
dc.subject | Sheep | |
dc.subject | Gene therapy | |
dc.title | Combined VEGF gene transfer and erythropoietin in ovine reperfused myocardial infarction | |
dc.type | Artículos de revistas | |
dc.type | Artículos de revistas | |
dc.type | Artículos de revistas | |